Clinical assessment of tolerability, immunological and cutaneous reactivity effects of an abbreviated schedule with Olea europaea native extract of subcutaneous immunotherapy

B. Sáenz-De San Pedro¹, M.P. Mur², l. Valverde³, M.A. Gonzalo-Garijo ⁴, M. Hernandez⁵, B. Madariaga ⁶, J.A. Asturias⁶, l. Begoña⁶, A. Martinez⁶, M.C. Gómez-Fernández maricruz.gomez@roxall.es⁶

Show more Authors information and Publication history

Doi
http://doi.org/10.23822/EurAnnACI.1764-1489.124

Summary
Objectives. To evaluate the tolerability and efficacy of Olea europaea subcutaneous immunotherapy (SCIT) on patients with rhinoconjunctivitis. Methods. In this open clinical trial patients were assigned to an abbreviated build-up scheme. The outcomes were: number, percentage, and severity of adverse reactions. Secondary outcomes included: changes in immunoglobulin titers and changes in dose-response skin prick tests. Results. Only 8 systemic reactions were registered, which represented 7/47 (14.9%) of patients and 8/429 (1.9%) of administered doses. Regarding immunological parameters the significant increases of sIgG and sIgG4 evidenced the changes in the patient immune system. Cutaneous reactivity decreased significantly. Conclusions. Olea europaea SCIT (Allergovac ® depot ROXALL Medicina España S.A.) showed a good safety and tolerability profile. Immunological changes with induction of blocking IgG and decreases in cutaneous reactivity were detected in the patients.

Key words
Olea europaea; subcutaneous immunotherapy; rhinoconjunctivitis; abbreviated schedule; depot extracts.

FULL TEXT